Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.

Slides:

Advertisements

Similar presentations

An Approach to Demonstration of Effectiveness

Advertisements

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.

429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.

Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,

OBESITY PREVENTION & CONTROL IN THE PEDIATRIC SETTING Ariana Raufi Warren Alpert Medical School of Brown University Hasbro Children’s Hospital.

Chapter 42 Pain.

What Do Toxicologists Do?

Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

An Introduction to Music Therapy Lori F. Gooding, Ph.D., MT-BC, NICU-MT.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

CONTRAST AGENTS AND RADIOPHARMACEUTICALS IN CHILDREN WITH CARDIAC DISEASE: SHOULD THEIR USE BE STUDIED? John C. Ring, MD, FAAP, FACC Associate Professor.

The NIH Roadmap for Medical Research

Copyright restrictions may apply A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency.

Stages of drug development

BC Jung A Brief Introduction to Epidemiology - XI (Epidemiologic Research Designs: Experimental/Interventional Studies) Betty C. Jung, RN, MPH, CHES.

Behavioral Health Issues and Pediatric Hospitalizations Stephen R. Gillaspy, PhD 11/05/09 Reaching Out To Oklahoma III Annual Pediatric Interdisciplinary.

Children Birth 4. Childbirth Setting And Attendants 99% of U.S. births occur in hospitals Other options –Freestanding birth center, home delivery Who.

A stroke is the leading cause of permanent impairment and disability. Pending a radical cure, patients recovering from a stroke will continue to require.

Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Screening Implementation: Referral and Follow-up What Do You Do When the Screening Test Is of Concern? Paul H. Lipkin, MD D-PIP Training Workshop June.

Implications of Pediatric Brain-Related Disorders for the Clinical Psychologist APA Convention Washington, DC August 6, 2011 Department of Pediatrics Case.

Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School

1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.

Overview Pediatric HIV Program & IMPAACT/ PACTG Vaccine Research Children’s National Medical Center, Washington, DC Dr.Hans ML Spiegel Director Special.

First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.

Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology.

MCHB Activities to Integrate Newborn Screening & Other Child Health Information Systems Deborah Linzer Senior Public Health Analyst U.S. Department of.

Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.

Copyright © 2002 University of Maryland School of Nursing. All rights reserved. Comparison of Pharmacology and Toxicology This material was developed at.

Copyright restrictions may apply Intranasal Midazolam vs Rectal Diazepam for the Home Treatment of Acute Seizures in Pediatric Patients With Epilepsy Holsti.

Detecting Individual Differences in Changes in Memory Functioning Dr. Len Lecci Professor of Psychology University of North Carolina Wilmington Director.

Drug - Device Combination Issues : Oncology Perspective Ramzi Dagher, M.D. DODP/CDER/FDA.

Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.

An agency of the European Union Presented by: Paolo Tomasi Data Safety Monitoring Boards / Data Monitoring Committees in paediatric studies Paolo Tomasi,

Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Pediatric Safety and Prevention Susan Beggs, RN MSN, CPN Fall 2009.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.

Outline Significance Definitions Challenges Next steps.

CJ411-Seminar 8 What are the major treatment strategies currently used for drug and alcohol abuse?

Perspectives on the Future of Pediatric Nursing Education and Practice Marion E. Broome, Ph.D., R.N. FAAN Distinguished Professor and Dean Indiana University.

Pediatric Safety and Prevention

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

B. Keith English, M.D. Chair, Pediatrics & Human Development Pediatric Cross-Campus Retreat Child Health Research at MSU 11/6/15.

Has been broadly defined as the generation of new knowledge using the scientific method to identify and deal with health problems.

NIAMS Extramural Scientific Planning Retreat 2013 April 4, 2013 Session 1: Strategies for Successful Rare Disease Clinical Trials.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Development of SafeT Kids Mobile App An injury prevention resource for parents Kerrie L. Roye Temple University.

Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.

The Regulation on Cell Therapy Products in Japan

Pediatric Drug Development: A Regulatory Perspective Tiffany R. Farchione, M.D. Medical Officer, Division of Psychiatry Products US Food and Drug Administration.

The Stages of a Clinical Trial

Division of Cardiovascular Devices

A stroke is the leading cause of permanent impairment and disability

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

Appropriate Regulation of Adjunctive Devices: Embolic Protection

Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS SHORT-TERM MEDIUM-TERM LONG-TERM.

Optimizing Outcomes With CT Imaging

Comments on design and sequence of biomarker studies

Why study Brain tumour Biology???

Drug Therapy in Pediatric Patients

Navigating the Journey

Presentation transcript:

Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration Center for Drug Evaluation and Research and The Office of Pediatric Therapeutics April 17,

2 Session I: Normal neurocognition and how it is measured in children of varying ages Presentations –Normal neonatal and infant neurocognitive development and measurements in this age group –Normal toddler, school age, and adolescent neurocognitive development and measurements in these age groups –NIH Toolbox for the assessment of neurological and behavioral function –The PING Study: Pediatric Imaging, Neurocognition, and Genetics Discussion Topics –The specific clinical areas for which current measurements of neurocognitive function have been most useful –The limitations present in the current standards of measurement of neurocognitive and behavioral function in children –The gaps, if any, in the current standards of age-specific measurement of neurocognitive and behavioral function in children

3 Session II: Neurocognitive signals from animal and human studies: Examples of the effect of medical interventions on long-term neurocognition Presentations –Long-term neurocognitive effects of therapy in survivors of acute lymphocytic leukemia: Novel approaches –Strategies for studying cognitive and behavioral effects of antiepileptic drugs –Neonatology follow up: Long-term effects of NICU treatment –CNS safety evaluation in drug development: Signals from animal studies that suggest the need for further investigations. Case study: Anesthetic-induced neurodegenration in the developing brain Discussion Topics –How signals from animal and human studies would prompt neurocognitive safety studies in children

Session III: Tools and strategies in the evaluation of neurocognitive and behavioral outcomes in products used to treat children Presentations –Regulatory considerations related to evaluation of long-term safety in pediatric patients –Environmental exposures and neurodevelopment al outcomes –What are the major challenges in the evaluation of long-term neurocognitive and behavioral outcome? Discussion –The adequacy of currently available tools to assess neurocognitive and behavioral outcomes –The potential endpoints that may be used in assessing short- term and long-term neurocognitive and behavioral outcomes –Study design considerations to optimally assess short-term and long-term neurocognitive and behavioral outcomes Appropriate length of studies; critical age windows of growth and development Additional study design issues: blinding, controls, and timing of testing 4